Łukasz Pyka

Łukasz Pyka

Auto-generated profile, based on publicly available information

Łukasz Pyka

3rd Department and Clinic of Cardiology, Faculty of Medical Sciences in Zabrze, Silesian Medical University, Katowice, Poland

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
MHMichał Hawranek
Michał Hawranek
MZMichal O. Zembala
Michal O. Zembala
MGMariusz Gasior
Mariusz Gasior
THTomasz Hrapkowicz
Tomasz Hrapkowicz
ŁPŁukasz Pyka
Łukasz Pyka
MZMarian Zembala
Marian Zembala
Comparison of coronary artery bypass grafting and percutaneous coronary intervention in patients with heart failure with reduced ejection fraction and multivessel coronary artery disease Comparison of coronary artery bypass grafting and percutaneous coronary intervention in patients with heart failure with reduced ejection fraction and multivessel coronary artery disease

1 November 2007 in Transplantation Proceedings
Verified
Journal Article
Closed access
MZMichał Zakliczyński
Michał Zakliczyński
AKA. Krynicka-Mazurek
A. Krynicka-Mazurek
ŁPŁ. Pyka
Ł. Pyka
DTD. Trybunia
D. Trybunia
PNPaweł Nadziakiewicz
Paweł Nadziakiewicz
MZM. Zembala
M. Zembala

7 April 2020 in Annals of Transplantation
Verified
Journal Article
Closed access
PDF file
ŁPŁukasz Pyka
Łukasz Pyka
MHMichał Hawranek
Michał Hawranek
BSBożena Szyguła-Jurkiewicz
Bożena Szyguła-Jurkiewicz
PDPiotr Desperak
Piotr Desperak
WSWioletta Szczurek
Wioletta Szczurek
PPPiotr Przybyłowski
Piotr Przybyłowski
BACKGROUND Cardiac allograft vasculopathy is a major cause of cardiac allograft rejection. Percutaneous coronary intervention has become the main form of treatment of significant focal lesions. Despite the significance of the problem, data remain scarce. With a large population of transplant recipients undergoing coronary angiography at our center, we decided to analyze the implications of the use of everolimus-eluting second-generation stents by performing 6-month clinical and angiographic follow-up. MATERIAL AND METHODS From December 2012 and August 2019, 319 patients after heart transplantation undergoing coronary angiography at our institution were analyzed. Subsequently, 22 patients underwent de novo angioplasty with second-generation everolimus-eluting stents. The primary study endpoint was angiographic restenosis as evaluated by quantitative coronary angiography. Secondary outcomes included binary restenosis, target lesion revascularization, and cardiac death during the follow-up period (6 months). RESULTS Patient comorbidities included hypertension (77.3%), type 2 diabetes mellitus (68.2%), dyslipidemia (68.2%), and obesity (31.8%). Primary success was obtained in all of the treated lesions. The analysis of quantitative coronary angiography after 6-month follow-up revealed low late lumen loss (0.22±0.40). Significant restenosis was observed in 1 of the cases. There were no deaths in the 6-month observation period. CONCLUSIONS In the analyzed population, invasive strategy with second-generation everolimus-eluting stents for de novo lesions in cardiac allograft vasculopathy resulted in a low rate of binary restenosis, low late lumen loss, and no deaths during the 6-month follow-up.

5 February 2019 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
ŁPŁukasz Pyka
Łukasz Pyka
Heart failure with preserved left ventricular ejection fraction (HFpEF) is an ongoing challenge. It has been recognized as a substantial clinical problem for ov

1 January 2023 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Open access
ŁPŁukasz Pyka
Łukasz Pyka
BHBartosz Hudzik
Bartosz Hudzik
SBStanisław Bartuś
Stanisław Bartuś
PBPaweł Buszman
Paweł Buszman
MGMarek Gierlotka
Marek Gierlotka
MGMariusz Gąsior
Mariusz Gąsior
The prevalence of atrial fibrillation (AF) in acute coronary syndrome (ACS) patients is increasing. Data on outcomes of anticoagulation in ACS patients with AF are lacking. The aim of our study was to investigate the prevalence of stroke, myocardial infarction, bleeding complications, and all-cause mortality in this population. PL-ACS and AMI-PL registries gather an all-comer population of ACS patients in Poland, exceeding half a million records. We have selected ACS survivors with concomitant AF on admission, divided them into subgroups with regard to the administered anticoagulation, and followed up with them for a 12-month period ( n = 13,973). Subsequently, groups were propensity score matched for age, sex, ejection fraction, diabetes, heart failure, renal impairment, and type of ACS. The study population was divided with regard to the administration of anticoagulation. Anticoagulation was prescribed in 2,466 patients (17.6%). The (D)OAC+ patients were younger; however, comorbidities were more prevalent in this group. The 12-month follow-up showed that the (D)OAC+ patients had significantly lower rates of all-cause mortality, myocardial infarction, and ischemic stroke, with no significant increase in bleeding events. After matching, the study groups consisted of 2,194 patients each and showed no differences in baseline characteristics. The outcomes of the 12-month observation were similar to the findings before matching. This all-comer national registry analysis shows that the use of guideline-recommended therapy and anticoagulation in ACS survivors with AF is associated with a lower rate of all-cause mortality, recurrent myocardial infarction, and ischemic stroke.

30 August 2025 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
MDMaciej Dyrbuś
Maciej Dyrbuś
ŁPŁukasz Pyka
Łukasz Pyka
AKAnna Kurek
Anna Kurek
JNJacek Niedziela
Jacek Niedziela
EAElżbieta Adamowicz-Czoch
Elżbieta Adamowicz-Czoch
MTMateusz Tajstra
Mateusz Tajstra
Background: The rate of long-term outcomes, including arrhythmic episodes following implantable cardioverter–defibrillator (ICD) device replacements, is often unknown. Thus, the aim of this manuscript was to evaluate the risk of ICD or cardiac resynchronization therapy–defibrillator (CRT-D) therapies in remotely monitored patients following device replacement. Methods: Data from 134 patients who underwent ICD/CRT-D replacement or upgrade were analyzed. Kaplan–Meier estimates, as well as Cox proportional hazards regression, were used to present long-term outcomes and predictors of study endpoints, these being all-cause mortality, and appropriate and inappropriate ICD/CRT-D therapies. Results: Among the cohort, 51.5% of patients received ICDs and 48.5% received CRT-Ds; the median (quartile 1–quartile 3) LVEF at replacement was 23.0% (18.0–28.0%). In 11 (8.2%) patients, the LVEF at replacement was higher than 35%. During the median (Q1–Q3) follow-up of 3.0 (1.4–5.0) years, 32.1% experienced appropriate and 6.0% experienced inappropriate therapies. The all-cause mortality rate was 38.0%, and appropriate antitachycardia pacing (ATP), a reduced baseline LVEF, and no history of myocardial infarction were independent predictors of death (odds ratios of 1.87 for appropriate ATP, 0.88 per 1% of the LVEF and 0.54 for a history of MI, respectively). The rate of appropriate device therapies was numerically lower in patients whose LVEF improved (19.8% vs. 33.3% and 0% vs. 6.5%, for appropriate and inappropriate therapies). An LVEF of >35% at replacement did not influence the analyzed outcomes. Conclusions: In patients who underwent ICD/CRT-D replacement, an improvement in LVEF was not identified as either a predictor of improved survival or of a lower risk of needing device therapies. Further stratification models are needed to evaluate the arrhythmic risk in patients after generator replacements.